PEA1Homo sapiens (Human)Cancer cell line
🤖 AI SummaryBased on 4 publications
Quick Overview
Human ovarian cancer cell line with BRCA1 mutation and platinum resistance.
Detailed Summary
PEA1 is a human ovarian cancer cell line derived from a high-grade serous carcinoma. It exhibits a BRCA1 mutation and demonstrates resistance to platinum-based chemotherapy. The cell line has been used in studies investigating the mechanisms of drug resistance and genomic instability in ovarian cancer. Research on PEA1 has contributed to understanding the role of BRCA1 mutations in cancer progression and therapeutic response. PEA1 is also utilized in studies exploring the tandem duplicator phenotype and its implications in tumor evolution and resistance to treatment.
Research Applications
BRCA1 mutation analysisPlatinum resistance mechanismsGenomic instability studiesTandem duplicator phenotype research
Key Characteristics
BRCA1 mutationPlatinum resistanceHigh genomic instabilityTandem duplicator phenotype
Generated on 6/19/2025
Basic Information
| Database ID | CVCL_2682 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Female |
Disease Information
| Disease | Ovarian cystadenocarcinoma |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | High-Grade Serous Ovarian Cancer |
| OncoTree Code | HGSOC |
DepMap Information
| Source Type | Sigma-Aldrich |
|---|---|
| Source ID | ACH-001628_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Cys242Alafs*5 (c.723delC) (p.S241fs) | Homozygous | - | Unknown, Unknown |
| MutationSimple | BARD1 | p.Trp218Ter (c.653G>A) | Unspecified | - | PubMed=25230021 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
14
D13S317
8
D16S539
12,13
D18S51
14,17
D19S433
12,13
D21S11
30
D2S1338
19,25
D3S1358
16,17
D5S818
11
D7S820
10
D8S1179
14
FGA
22,25
Penta D
13,15
Penta E
7,12,13
TH01
9
TPOX
8,12
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Wang P., Birrer M.J., Paulovich A.G.
Cell Rep. Med. 2:100471.1-100471.32(2021).
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Cell Rep. 18:2343-2358(2017).
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Helleman J.
PLoS ONE 9:E103988-E103988(2014).
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mills G.B., Hennessy B.T.
Mol. Oncol. 7:567-579(2013).
The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.
J. Pathol. 226:703-712(2012).
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Langdon S.P., Huntsman D.G., Brenton J.D.
Oncogene 29:4905-4913(2010).
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.
Cancer Res. 48:6166-6172(1988).